Clinical trials: Oral Cavity Carcinoma
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Head and Neck Cancer
Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002659
- Testing
- cisplatin-e therapeutic implant
- Where
- 28 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Matrix Pharmaceutical
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
This is the first time in patient study to assess the safety, tolerability and preliminary efficacy of AZD3759 in patients with advanced Non Small Cell Lung Cancer (NSCLC) In this study, patients with Leptomeningeal Metastasis…
- Trial name
- BLOOM (NCT02228369)
- Testing
- AZD3759, AZD9291
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
A single-arm, open-label, multicenter, phase II study. Treatment with LDK378 750 mg qd continued until the patient experienced unacceptable toxicity that precluded further treatment, discontinued treatment at the discretion of…
- Trial name
- NCT01685060
- Testing
- LDK378
- Where
- 52 sites in United States, Canada and 10 more
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer, Head and Neck (HNSCC)
APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma
This Phase 3, multicenter, randomized, open-label study evaluates APG-157 in adults with newly diagnosed locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
- Conditions
- Head and Neck Cancer, Head and Neck (HNSCC), Oropharyngeal, Oral Cavity
- Trial name
- NCT07667296
- Testing
- APG-157, Surgery, Radiation/Chemotherapy
- Volunteers
- 826 people
- Sponsor
- Aveta Biomics, Inc.
Non-Small-Cell Lung Carcinoma
Iressa Versus Docetaxel (Taxotere)
The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based…
- Trial name
- NCT00076388
- Testing
- Gefitinib, Docetaxel
- Where
- 162 sites in United States, Argentina and 23 more
- Volunteers
- 1,440 people
- Sponsor
- AstraZeneca
Lymphoma, Large-Cell, Anaplastic, Carcinoma, Non-Small-Cell Lung
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
The purpose of this study is 2-fold: initially, in the dose escalation phase, the goal is to determine the safety profile of orally administered brigatinib, including: the maximum tolerated dose (MTD), dose limiting toxicities…
- Trial name
- NCT01449461
- Testing
- Brigatinib
- Volunteers
- 137 people
- Sponsor
- Ariad Pharmaceuticals
Renal Cell Cancer, Castrate Resistant Prostate Cancer
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care.
- Conditions
- Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
- Trial name
- NCT04969315
- Testing
- TT-10, TT-4
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Portage Biotech
Advanced Solid Tumor, Metastatic Solid Tumor
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
- Trial name
- NCT06577987
- Testing
- CID-078 Monotherapy
- Where
- 10 sites in United States
- Volunteers
- 220 people
- Sponsor
- Circle Pharma
Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
Safety and Efficacy of APG-157 in Head and Neck Cancer
The purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \& Neck Cancer of oral cavity…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT05312710
- Testing
- APG-157
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Aveta Biomics, Inc.
Triple Negative Breast Cancer, Hepatocellular Carcinoma
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable…
- Trial name
- NCT03318562
- Testing
- eFT508
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Effector Therapeutics
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase 2, open-label, multicenter study to assess the efficacy and safety of second/third-line treatment with nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab…
- Trial name
- abound2L+ (NCT02250326)
- Testing
- nab-paclitaxel IV, CC-486, Duravalumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 240 people
- Sponsor
- Celgene
Head and Neck Cancer
Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
The purpose of the study is to evaluate Medpulser electroporation (EPT) with bleomycin with regard to local tumor recurrence, disease-free survival, and overall survival rates versus surgery in recurrent or secondary primary…
- Trial name
- NCT00198315
- Testing
- Medpulser electroporation with Bleomycin, Tumor surgical excision
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Inovio Pharmaceuticals
Non Small Cell Lung Cancer
Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer
The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens.
- Trial name
- FORTIS-M (NCT00707304)
- Testing
- Talactoferrin
- Where
- 189 sites in United States, Australia and 21 more
- Volunteers
- 742 people
- Sponsor
- Agennix
Locally Advanced or Metastatic NSCLC
Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole
To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of ASK120067 and its metabolite CCB4580030 in healthy subjects.
- Trial name
- NCT05631678
- Testing
- Rifampicin; ASK120067, ASK120067;itraconazole
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC
This is a prospective, randomized, multicenter real-world study, which aims to investigate the efficacy and safety of Jinfukang oral liquid combined with chemotherapy as first-line treatment regimen for patients with…
- Trial name
- NCT05098990
- Testing
- Jinfukang oral liquid, Platinum-based doublet chemotherapy
- Volunteers
- 328 people
- Sponsor
- China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Cholangiocarcinoma, Cholangiocarcinoma Non-resectable
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
ABC-108 is a single-arm Phase IIA clinical study of ABC294640 (Yeliva ®, opaganib) alone and in combination with hydroxychloroquine sulfate (HCQ) in the treatment of cholangiocarcinoma (CCA).
- Conditions
- Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic
- Trial name
- NCT03377179
- Testing
- ABC294640, Hydroxychloroquine Sulfate 200 MG
- Where
- 5 sites in United States
- Volunteers
- 65 people
- Sponsor
- RedHill Biopharma Limited
Hepatocellular Carcinoma
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
The purpose of this study is to determine whether TAC-101 as a second line therapy for participants who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular…
- Trial name
- NCT00687596
- Testing
- TAC-101
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Solid Tumor Cancers, Medulloblastoma
An East Asian Study of LDE225
The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e., Japanese and Chinese/Taiwanese) with advanced…
- Conditions
- Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
- Trial name
- NCT01208831
- Testing
- LDE225
- Where
- 4 sites in Hong Kong, Japan and 1 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Thymic Carcinoma
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
The intent of the study is to assess the antitumor activity of PHA-848125AC as second-line treatment in patients with recurrent or metastatic, unresectable thymic carcinoma previously treated with chemotherapy.
- Trial name
- NCT01011439
- Testing
- Milciclib Maleate
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 72 people
- Sponsor
- Tiziana Life Sciences LTD